Oramed Pharmaceuticals Inc (ORMP)

[midastouch017]

Jim Cramer comments propel Oramed Pharmaceuticals

Aug. 10, 2021 9:08 AM ET
Oramed Pharmaceuticals Inc. (ORMP)

By: Dulan Lokuwithana, SA News Editor

https://seekingalpha.com/news/3728191-jim-cramer-comments-propel-oramed-pharmaceuticals

Oramed Pharmaceuticals (NASDAQ:ORMP) appears to extend gains for the fourth consecutive day thanks to favorable views made by TV personality Jim Cramer on CNBC’s “Mad Money” on August 05.

Responding to a question on the company’s COVID-19 therapy, Jim Cramer called Oramed (ORMP) “a good company,” and recommended the stock.

“Because of some of the things I’m doing with the American Migraine Foundation and some other things, that’s a good company, and I really like what they’re up to and I think you should go for it,” Cramer remarked in the “lightning round” segment of the program.

In two of the past three days, Oramed (ORMP) has made double-digit gains in percentage terms, and in the year so far, the stock has more than quadrupled in value, as shown in the graph. Oramed (ORMP) has added another ~15.0% in the pre-market today.

In July, the company announced that its majority-owned company Oravax Medical would start clinical trials for the oral COVID-19 vaccine candidate, first in Israel and then in additional sites in other countries.

Now Read: Oramed Pharmaceuticals to join Russell 2000 and 3000 Index